Conjugate Vaccines Market

The growth of the conjugate vaccines market is attributed to several key factors, such as Strong Disease Burden in Target Populations and Inclusion in National Immunization Programs.

Several key players in the conjugate vaccines market with a strong footprint include Pfizer Inc. (US), Merck & Co., Inc. (US), GSK (UK), Sanofi (France), Serum Institute of India (India), Daiichi Sankyo Company Limited (Japan), Panacea Biotec (India), Biological E Limited (India). Companies in the conjugate vaccines market are scaling beyond traditional vaccine production into high-throughput, automated platforms covering advanced polysaccharide conjugation, carrier protein manufacturing, multivalent formulation assembly, and specialized reagents targeting complex biologics and combination conjugate workflows. By adding new production capacity and launching integrated hardware-software ecosystems, they aim to extend regional presence, covering conjugate vaccine development programs across discovery, translational research, clinical trials, and public health applications to support precision immunization strategies against pneumococcal, meningococcal, and Hib pathogens.

To know about the assumptions considered for the study download the pdf brochure

In January 2026, Merck completed the acquisition of Cidara Therapeutics to bolster its conjugate vaccine pipeline, enhancing capabilities against resistant pneumococcal strains.

 Pfizer, Inc. (US)

Pfizer Inc. leads the conjugate vaccines market with cutting-edge CRM197 conjugation platforms, automated high-throughput assembly lines for PCV20/21 (Prevnar/CAPVAXIVE), and integrated digital twins for real-time process analytics. The company's expanded facilities in Kalamazoo, Michigan, and Portage, Michigan, position it as a premier partner for biopharma and global health entities requiring massive-scale, compliant production to power national immunization campaigns against invasive pneumococcal disease.

Merck & Co. Inc (US)

Merck & Co., Inc. stands as a dominant conjugate vaccines player, combining advanced tetanus toxoid carrier systems, robotic fill-finish operations, and AI-driven manufacturing execution systems to produce scalable Vaxneuvance (PCV15) and next-generation multivalent formulations. Through new capacity additions in Durham, North Carolina, Merck establishes itself as an end-to-end solutions provider for public health organizations and biopharma partners seeking reliable, high-volume supply to advance pediatric and adult immunization objectives.

GSK plc (UK)

GSK excels in the conjugate vaccines arena via proprietary Menitorix/Menveo platforms, continuous manufacturing for Hib-MenC conjugates, and advanced PAT-enabled quality control suites for serogroup consistency. Strategic North American footprint expansions in Rockville, Maryland, solidify GSK's role as a comprehensive collaborator for developers and health authorities needing robust, flexible production infrastructure to support precision meningococcal and combination vaccine deployment strategies.

Market Ranking

Leading conjugate vaccine companies are advancing beyond traditional production into high-throughput, automated platforms for polysaccharide activation, CRM197 carrier conjugation, multivalent blending, and specialized reagents supporting complex biologics workflows. Pfizer Inc. pioneers PCV20/21 expansions through Kalamazoo and Andover upgrades, enabling agile deployment of Prevnar/CAPVAXIVE against invasive pneumococcal disease. Merck & Co., Inc. integrates tetanus toxoid platforms with facilities in Durham, North Carolina, for scalable Vaxneuvance (PCV15) supply, targeting both pediatric and adult schedules. GSK leverages MenACWY/Hib systems via Rockville enhancements for next-gen meningococcal innovation. Sanofi optimizes polysaccharide fermentation and Swiftwater conjugation lines for Menveo combos. Globally, Serum Institute of India streamlines 20-valent PCV platforms through Pune expansions and WHO-prequalified processes for massive tender supply. These hardware-software ecosystems span discovery to deployment, positioning them as one-stop partners that accelerate precision immunization against IPD, meningitis, and Hib across the biopharma and public health sectors.

Related Reports:

"Conjugate Vaccines Market by Disease (Pneumococcal, DTP, Meningococcal Disease), Type (Monovalent, Multivalent), End User (Adult, Pediatric) - Forecast to 2030" 

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com